주 메뉴 바로가기 본문 바로가기 하단 바로가기

Pipeline

We look for ways to promote health and happiness for all

Antibody Biosimilars

Celltrion will continue to blaze new trails and discover new opportunities.
Project INN Original Major Indications Status Clinical Info
CT-P39 Omalizumab XOLAIR® Asthma, Urticaria Phase1·3 외부링크연결
CT-P17 Adalimumab HUMIRA® Rheumatoid arthritis, Psoriatic arthritis, IBD Phase3 외부링크연결
CT-P16 Bevacizumab AVASTIN® Metastatic Colorectal Cancer, Metastatic Breast Cancer, NSCLC Phase3 외부링크연결
CT-P41 Denosumab

PROLIA®

Osteoporosis, Bone Loss Phase1
CT-P43 Ustekinumab

STELARA®

Psoriasis, Crohn's disease, Ulcerative colitis Phase1
  • * Registered trademarks of reference products
  • REMICADE® is a registered trademark of JANSSEN
  • AVASTIN® is a registered trademark of GENENTECH
  • HUMIRA® is a registered trademark of ABBVIE
  • XOLAIR® is a registered trademark of NOVARTIS
  • PROLIA® is a registered trademark of AMGEN

New Antibodies

Celltrion will continue to blaze new trails and discover new opportunities.
Project Indications Status Clinical Info
CT-P27 Pandemic·Seasonal influenza Phase2
CT-P59 COVID-19 Phase2·3

IMDs

Celltrion will continue to blaze new trails and discover new opportunities.
Project Indications Status Clinical Info
CT-G20 Cardiomyopathy Phase1